Walgreens, taken private by Sycamore Partners for $10 billion in August 2025, is accelerating its restructuring — cutting 628 positions and splitting into five standalone companies as the PE firm reshapes one of America's largest pharmacy chains.

The five entities: Walgreens (retail pharmacy), Shields Health Solutions (specialty pharmacy), CareCentrix (home health), VillageMD (primary care clinics), and Boots Group (U.K. retail pharmacy). Each will operate independently, with a potential Boots spin-off or sale expected by end of 2026.

The layoffs hit primarily at the Deerfield, Illinois headquarters and a Houston logistics center. Retail veteran Mike Motz replaced CEO Tim Wentworth, bringing experience from Staples U.S. Retail and Shoppers Drug Mart. The store closure initiative, already underway before the take-private, is being finalized under Sycamore's direction.

The restructuring illustrates PE's playbook for healthcare retail: acquire at distressed valuations, separate business lines to maximize individual unit value, cut overhead, and prepare each unit for eventual exit. For healthcare providers: understand which of these five entities touches your supply chain, your patients' pharmacy access, and your referral networks.

Read the full article →